International Journal of Risk & Safety in Medicine 16 (2004) 247–259
Recent U.S., Canadian and British regulatoryagency actions concerningantidepressant-induced harm to self andothers: A review and analysis 1
Founder and Director Emeritus, The International Center for the Study of Psychiatry and Psychology,101 East State Street, No. 112, Ithaca, NY 14850, USA1. Introduction
Drug regulatory agencies in the United States (FDA), Canada (Health Canada) and Great Britain
(MHRA) have significantly upgraded their warnings concerning antidepressant-induced suicidality inchildren. Furthermore, the U.S. and Canada have confirmed an antidepressant-induced stimulant or ac-tivation cluster of adverse events in children and adults that includes hostility and aggression. Althoughmost attention has been given to warnings about drug-induced suicidality, more emphasis needs to beplaced upon U.S. and Canadian warnings about the potential production of stimulation and mania withhostility and aggression. This report examines these recent regulatory events and related research. It alsoupdates the author’s most recent review of antidepressant-induced behavioral and mental abnormali-ties .
The SSRIs (selective serotonin reuptake inhibitors) have been the major focus of attention by the reg-
ulatory agencies. With some exceptions in regard to the severity or frequency of adverse reactions, theSSRIs can be treated as one group in regard to their profile of adverse drug reactions2. The SSRIs includefluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa)and escilalopram (Lexapro). In recent reports issued by the FDA  four other potentially stimulatingantidepressants were found to produce similar adverse behavioral and mental effects and were includedin the group: venlafaxine (Effexor), mirtazapine (Remeron), Wellbutrin or Zyban (bupropion) and nefa-zodone (Serzone).
1The present paper appears simultaneously in Ethical Human Psychology and Psychiatry, Journal of the International Center
for the Study of Psychiatry and Psychology and is published with permission of Springer Publishing Company, New York, NY,USA.
2Marangell, Yudofsky and Silver  observed, “All SSRIs have a similar spectrum of efficacy and a similar side-effect
profile” (p. 1035). Exceptions include the greater withdrawal problems associated with shorter acting SSRIs (e.g., Paxil) andthe greater severity and/or frequency of psychiatric adverse reactions associated with some (e.g., Paxil).
0924-6479/04/$17.00 2004 – IOS Press and the authors. All rights reserved
P.R. Breggin / Antidepressant-induced harm to self and others2. Recent research findings 2.1. Healy reevaluation of SSRI clinical trials for Paxil-induced suicidality and violence
Healy and Whitaker  reviewed all available meta-analyses, epidemiological studies and random-
ized controlled trials (RCTs) to determine if SSRI antidepressants increase the rate of suicide and sui-cidal acts. In one analysis, they pooled the data previously obtained from the FDA database for antide-pressants [25–27]. For all SSRIs, suicides and suicide attempts occurred in 1.53% of patients and forplacebo they occurred in 0.47% of patients. The odds ratio for a completed suicide while taking an SSRIantidepressant (including venlafaxine) compared to placebo was 2.46. The odds ratio for suicidal actswas 2.22 compared to placebo. In comparing all of the new antidepressants to placebo, the odds ratiofor a suicide was 4.40 (p = 0.0125) and the odds ratio for suicidal acts was 2.39 (p
of the newer antidepressants had higher percentage of suicide and suicidality than placebo: sertraline(0.44%/0.25%), paroxetine (1.52%/0.54%), nefazodone (0.60%/0.11%), mirtazapine (1.53%/0.61%),citalopram (2.38%/1.59%), fluoxetine (0.91%/0%) and venlafaxine (1.40%/0.41%). The relative risk ofsuicidal acts was statistically significant for sertraline, paroxetine and fluoxetine compared to placebo. For bupropion there were three suicides in the treatment group and none in the placebo group, and nodata on suicide attempts.
Healy and Whitaker  also re-evaluated epidemiological studies from the United Kingdom. They
found increased rates of suicide and suicidal behavior on SSRI antidepressants.
In a letter to the FDA Healy  reviewed all available Paxil (British trade name Seroxat) controlled
clinical trials for SSRIs for children and teenagers. In Protocol 329 (1993-late 95/early 1996) Paxilwas ineffective in children. According to Healy, “The results in terms of hazards were also conclusive;Seroxat/Paxil had a statistically significant excess of suicidal acts compared to comparators” (p. 5). There were five suicidal acts among 93 drug-treated children, none among 89 children on placebo,and one among 184 children on placebo or imipramine. “Furthermore roughly 10% of the children hadpsychiatric side effects on Seroxat/Paxil, which is particularly significant against a background of failureto demonstrate that the drug worked” (p. 5).
Healy pointed out, “In the published version of 329 , suicidality disappears under a carpet of
emotional lability” (p. 5). After Protocol 329 was disclosed on British television (Panorama), the MHRAobtained the suicide data hidden under the term “emotional lability”, leading the agency to issue its firstwarning about Paxil.
Healy also reported that other protocols that may have been even more negative than Protocol 329
(e.g., Protocols 377, 511, and 716) were never made available to regulatory agencies or published. Hefound a systematic attempt by the manufacturer GlaxoSmithKline to hide the risk of suicide by recodingsuicidal behavior as emotional lability.
Healy pooled all available data from controlled clinical trials for the treatment of depression in children
involving several SSRIs (Paxil, Zoloft, Celexa, and Prozac). He reviewed 931 depressed children treatedwith SSRIs and 811 treated with placebo. There were 52 suicidal acts on SSRIs compared to 18 onplacebo for a comparative rate of 5.6% versus 2.2%. The odds ratio was 2.51 (p = 0.000899).
Healy also pooled data from clinical trials for the treatment of anxiety in children. There were 10
suicidal acts among 638 anxious patients treated with SSRIs and one among 562 taking placebo. Thecomparative rates were 1.6% versus 0.18% for an odds ratio of 11.31 (p = 0.0156). P.R. Breggin / Antidepressant-induced harm to self and others
When the depressed and anxious pediatric patients were combined, there was a 4% rate of suicidal
acts in the treated group and 1.4% in the placebo group. The relative risk for suicidal acts among thechildren was 2.9 times greater for SSRIs.
Healy found “While the rate of suicidal acts is higher in pediatric trials of depression, the relationship
between active treatment and placebo is the same in both adult and pediatric groups” (p. 9). In addition,the rate in children increased from the 6–12 age group to the teenage years, indicating that the problemworsened with age.
In Protocol 329 and other Paxil pediatric studies Healy  found that “aggressive events appear under
the heading of hostility, a term that covers homicidal acts, homicidal ideation and aggressive events”(pp. 5–6). Healy analyzed data on acts of hostility from four different protocols on GlaxoSmithKline’swebsite, plus one additional protocol. He counted 31 reported hostile episodes among 524 Paxil-treatedpatients and only 2 among 526 placebo patients. The odds ratio was 15.54 (p = 0.000001). Healy states:“These results are in line with the analyses of data conducted by Andrew Mosholder of the FDA andby the MHRA, but excludes a number of drugs these authors included. This analysis represents a muchpurer set of SSRI drugs, and more data on SSRI drugs than has been available to other reviews” (p. 10).
Healy emphasized that SSRI-induced agitation tends to be dose dependent in healthy volunteers and
patients (making suicidal and violent acts potentially dose dependent). He found that a large proportionof these adverse events take place early in treatment or during dose changes, including reductions orwithdrawal. 2.2. Jureidini et al. (2004) review the risk/benefit ratio
Jureidini et al.  reviewed the literature and found six placebo-controlled clinical trials for children
involving the newer antidepressants. Their analysis concluded that a “major benefit” from these drugswas unlikely and that the adverse effects reported in the clinical trials outweighed any possible “smallbenefit”. They came out against recommending antidepressants as a “treatment option, let alone as firstline treatment” (p. 882). In summary, “Antidepressant drugs cannot confidently be recommended as atreatment option for childhood depression” (p. 879). They found that “Adverse effects have been down-played” and observed that “A more critical approach to ensuring the validity of published data is needed”(p. 879). Among the adverse effects, they cited the activation syndrome. 2.3. Whittington et al. (2004) metanalysis of the risk/benefit ratio
Whittington et al.  conducted a metanalysis of data from placebo-controlled clinical trials in chil-
dren that were published in peer-reviewed journals or included in a review of unpublished studies onthe website of the Committee on Safety of Medicines (CSM, Great Britain). They found that the datasupported a “favourable risk–benefit” ratio for Prozac on the basis of two published clinical trials, aswell as unpublished data. They found equivocal, weak, or unfavourable risk–benefit profiles based onstudies of paroxetine, sertraline, citalopram and venlafaxine. They concluded, “Greater openness andtransparency with respect to all intervention studies is needed” (p. 1341).
Whittington and his colleagues should have included Prozac among the drugs with unfavorable risk–
benefit ratios; but they may have missed an observation buried in the discussion of dropouts in a paper byEmslie et al. from 1997 indicating that 6% of the children discontinued because of manic symptoms . This is an extraordinarily high frequency for a very dangerous adverse reaction. P.R. Breggin / Antidepressant-induced harm to self and others
In addition, in a prepublication paper delivered at a psychiatric conference prior to the publication of
his study in 1997, Emslie reported in 1995 that the clinical trial found not only a 6% rate of mania but anincreased rate of aggression in children taking Prozac . However, he failed to make any mention ofthe increased aggression in the published version . In response to Emslie’s prepublication remarks,I wrote a letter to Clinical Psychiatry News challenging Emslie’s conclusion that Prozac was safe forchildren despite drug-induced aggression and mania . At the conclusion of my letter, the editorscommented that Emslie “declined to respond”.
Jureidini et al.  point out that funding for the 1997 Emslie et al. publication was “attributed to
National Institute of Mental Health, but that FDA data show the study was sponsored by Eli Lilly” andthat funding for an other publication on the subject by Emslie et al.  came directly from the drugcompany with “all authors employed by or otherwise contracted to Eli Lilly” (Table, p. 880). Eli Lilly hasa history of hiding suicidality data in its Prozac trials under false headings such as no drug effect [3,20]. 2.4. Moore’s (2004) analysis of FDA spontaneous reporting system data
Moore  analyzed all spontaneous reports to the FDA for the six most commonly prescribed anti-
depressant drugs: sertraline, paroxetine, fluoxetine, citalopram, bupropion, and venlafaxine. From No-vember 1997 through December 2002 the FDA received 44,026 reports. Children accounted for 5.2% ofall reports. Key findings of the study included the following (p. 1):
– Among all ages, the six target drugs were suspected of triggering 3,309 episodes of suicide, at-
tempted suicide, or hostile, violent or other abnormal behaviors. A total of 353 cases were in chil-dren under 18 years of age. – Suicidal/aggressive behaviors were reported in children at more than twice the expected rate given
the drugs’ medical use in this group. – Like suicidal/aggressive behaviors, mania/euphoria was also reported more than twice as frequently – Taken together, suicidal/aggressive behaviors and mania/euphoria describe potentially dangerous
changes in mood or personality suspected of being associated with the six target drugs. In children,such reports accounted for 24% of all reported adverse events.
Taken in the context of other confirmatory findings, Moore believes that the evidence provides a strong
warning signal concerning the potential of the newer antidepressants to cause suicidal, aggressive, andmanic behaviors in children. 3. FDA-sponsored research presented at the September 13–14, 2004 FDA hearings
At the follow-up FDA hearing on September 13, 2004, Hammad  reported in 2004 on the FDA-
sponsored Columbia project that analyzed 25 trials with pediatric patients from nine drug developmentprograms. The project also performed a reclassification study of drug company adverse reaction reportsfor Prozac. The Columbia project found that the antidepressants produced a statistically significant 2–3%increase in the risk of suicidality in children, including suicidal ideation and actions. There were nocompleted suicides in the group. P.R. Breggin / Antidepressant-induced harm to self and others3.2. Mosholder studies of SSRI-induced suicidality
Mosholder of the FDA Office of Drug Safety (ODS) conducted an in-house study that indicated an
increased rate of suicidality for SSRIs in controlled clinical trials . The FDA did not allow Mosholderto publish his results or to present them at the initial FDA hearing on February 12, 2004. At the follow-upFDA hearing on September 13, 2004 Mosholder presented his findings, bolstered with additional datafrom the Columbia study of suicidality in pediatric trials and an officially approved FDA analysis bythe Division of Neuropharmacologic Drug Products (DNDP) . Mosholder and the DNDP evaluatedall available clinical trials for sertraline, paroxetine, fluoxetine, citalopram, and venlafaxine. Mosholderconcluded that his original ODS study and the more recent DNDP analysis both indicated an associationof suicidality with antidepressant drug treatment in short-term, placebo-controlled trials in children andadolescents under age eighteen (pediatric patients).
Based on the Columbia, ODS and DNDP studies, Mosholder calculated the risk as equivalent to one
event of suicidality for every twelve years of patient treatment. 3.3. The actual rates of suicidality are higher
The estimated rates for suicidality in the Columbia, Mosholder and DNDP studies are far below the
actual rates. The available data was not based on the original clinical reports from the principal investi-gators in the field. Instead, the researchers relied on summaries of these events written by drug companyofficials. However, drug company officials have laundered suicidality data for Prozac  and for Paxil[20,28] by coding them under misleading terms such as no drug effect (Prozac) or emotional lability(Paxil). Furthermore, the dropout rates in Prozac studies have been very high, and follow up studies onthe dropouts non-existent, so that it is impossible to know how many suicidal acts took place a day ormore afterward in patients who dropped out in a worsened condition. On page 9 of the report by Healyin 2004  one can read that Eli Lilly (Prozac) and GlaxoSmithKline (Paxil) submitted suicide data forplacebo groups that originated before or after rather than during the clinical trials. Furthermore, Healynoted that the FDA-sponsored analyses ignored the impact of dose reduction and withdrawal althoughGlaxoSmithKline in its letter to healthcare professions in Great Britain states that dose lowering maylead to suicidality.
The FDA has not done any follow-up studies of adult patients and has thus far refused offers from this
author  and from the British Medical Journal  to produce drug-company generated data indicatingincreased suicide rates among adults exposed to SSRIs.
Thomas Laughren , Team Leader of the FDA’s Psychiatric Drug Products Group, Division of
Neuropharmacologic Drug Products, noted at the September 2004 FDA hearings that suicidality wasespecially a problem “at the beginning of therapy, or at times of dose changes”. He also emphasized therisk “in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt inonset, or was not part of the patient’s presenting symptoms”. He further connected suicidality to the de-velopment of the stimulant or activation syndrome: “Observe for emergence of other symptoms as well,including: anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity,akathisia (psychomotor restlessness), hypomania and mania” (p. 2).
Laughren confirmed the failure to find efficacy demonstrated for any of the drugs in the pediatric
trials. Only three of fifteen trials reviewed were positive for efficacy in children suffering from majordepressive disorder. P.R. Breggin / Antidepressant-induced harm to self and others4. The FDA takes action 4.1. The FDA public health advisory describes activation (stimulant) syndrome
On March 22, 2004 the FDA published a Talk Paper entitled, “FDA Issues Public Health Advisory on
Cautions for the Use of Antidepressants in Adults and Children” . Note that the advisory focusedon adults as well as children. The FDA stated: “The agency is also advising that these patients be ob-served for certain behaviors that are known to be associated with these drugs, such as anxiety, agitation,panic attacks, insomnia, irritability, hostility, impulsivity, akathisia (severe restlessness), hypomania, andmania”.
The FDA describes these adverse reactions as “known” – that is, scientifically demonstrated or es-
tablished. The list confirms the existence of the antidepressant-induced stimulant effect or activationsyndrome3 in adults and children with its potential to cause hostility and related behaviors. 4.2. The implications of irritability, akathisia and mania
Three specific terms that appear in several FDA publications are closely related to violence. First, the
term “irritability” when used in psychiatry specifically includes heightened aggression. The AmericanPsychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, IV-TR (DSM-III-TR)4  , for example, defines irritability as “persistent anger, a tendency to respond to eventswith angry outbursts or blaming others, or an exaggerated sense of frustration over minor matters”(p. 349).
Second, “akathisia” is also associated with violence. Akathisia is a drug-induced state of inner ir-
ritability and agitation that usually (but not always) manifests itself in hyperactivity. The DSM-III-TRstates that SSRI antidepressants can cause akathisia and that akathisia can result in severe behavioralabnormalities, including suicide and aggression: “Akathisia may be associated with dysphoria, irritabil-ity, aggression, or suicide attempts. It also described, “worsening of psychotic symptoms or behaviordyscontrol” (American Psychiatric Association [1, p. 801]).
Third, drug-induced mania can cause violence and suicide. The DSM-III-TR contains many refer-
ences to antidepressant-induced mood disorders including mania and depression (e.g., American Psy-chiatric Association, 2000, pp. 361 and 406; footnotes on charts, pp. 362, 365 and 368). For example,the DSM-IV-TR section on Manic Episode reaffirms, “Symptoms like those seen in a Manic Episodemay also be precipitated by antidepressant treatment such as medication . . .” (p. 361). The same sectionobserves that manic episodes can produce “assaultive behavior” (p. 358) and “The person may be hostileand physical threatening to others. Some individuals, especially those with psychotic features, may be-come physically assaultive or suicidal” (p. 359). Also, “Mood may shift rapidly to anger or depression”(p. 359).
3Chesney, in 2004 , speaking on the Pediatric Drug Committee at the FDA hearings, confirmed that the advisory com-
mittee considered aggression and hostility to be aspects of the activation syndrome.
4The DSM-III-TR represents a scientific consensus of experts in the field. The introduction states, “The utility and credibility
of DSM-IV require that it focus on its clinical, research, and educational purposes and be supported by an extensive empiricalfoundation” (p. xxiii). Furthermore, it states, “It must be noted that the DSM-IV reflects a consensus about the classification anddiagnosis of mental disorders derived at the time of its initial publication” (p. xxiii). The DSM-IV-TR endorses its application tothe legal arena: “By providing a compendium based on a review of the pertinent clinical and research literature, DSM-IV mayfacilitate the legal decision-makers’ understanding of the relevant characteristics of mental disorders” (p. xxiii). P.R. Breggin / Antidepressant-induced harm to self and others4.3. The FDA further confirms SSRI-induced abnormal behavior, including violence and aggression
Following its March 22, 2004 Public Health Advisory, the FDA continued to emphasize its conclusions
that SSRIs can cause suicidality in children and a variety of stimulant or activation symptoms in adultsand children that are implicated in both suicide and violence.
On October 15, 2004 (updated October 28, 2004) the FDA made official its “labeling change request”
for antidepressants requiring drug companies to update their labels with specific language . In itshighest level of warning, a black box, the FDA unequivocally endorsed causality for antidepressant-induced suicidality: “Antidepressants increase the risk of suicidal thinking and behavior (suicidality) inchildren and adolescents with major depressive disorder (MDD) and other psychiatric disorders” (p. 1).
The FDA labeling request also includes the following: “All pediatric patients being treated with anti-
depressants for any indication should be observed closely for clinical worsening, suicidality, and unusualchanges in behavior, especially during the initial few months of a course of drug treatment, or at timesof dose changes, either increases or decreases” (p. 2).
The label update suggested changing the therapeutic regimen, or stopping the medication, in med-
icated patients with worsening depression or suicidality “especially if these symptoms are severe, abruptin onset, or were not part of the patient’s presenting symptoms” (p. 3).
The new antidepressant labels will also be required to contain the following warning statement about
activation or stimulation, including hostility and aggression: “The following symptoms, anxiety, agi-tation, panic attacks, insomnia, irritability, hostility (aggression), impulsivity, akathisia (psychomotorrestlessness), hypomania, and mania, have been reported in adult and pediatric patients being treatedwith antidepressants for major depressive disorder as well as for other indications, both psychiatric andnon-psychiatric” (p. 3).
The reference to “non-psychiatric” indications confirmed that the activation syndrome, including hos-
tility and aggression, can occur in patients who have not been given psychiatric diagnoses. This con-tradicted the myth that these reactions are confined to mentally disordered individuals and specificallyindividuals who are being treated for depression.
In its letter requiring a label change, the FDA also summarized the results of its analyses of controlled
clinical trials presented at the September 2004 hearing : “Pooled analyses of short-term placebocontrolled trials of nine antidepressant drugs (SSRIs and others) in children and adolescents with MDD,OCD and other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealeda greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the firstfew months of treatment in those receiving antidepressants. The average risk of such events on drug was4%, twice the placebo risk or 2%. There was considerable variation in risk among drugs, but a tendencytoward an crease for almost all drugs studied”.
The FDA repeated and summarized these themes in the label section on information for patients and
their families: “Patients and their families should be encouraged to be alert for the emergence of anx-iety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania,and other unusual changes in behavior, worsening of depression, and suicidal ideation, especially earlyduring antidepressant treatment and when the dose is adjusted up or down. Families and caregivers ofpatients should be advised to observe for the emergence of such symptoms on a day-to-day basis, sincechanges may be abrupt. Such symptoms should be reported to the patient’s physician, especially if theyare severe, abrupt in onset, or were not part of the patient’s presenting symptoms” (p. 5).
On November 3, 2004, the FDA published its “FDA Proposed Medication Guide: About Using An-
tidepressants in Children and Adults” . In a heading entitled “What to Watch out for in Children
P.R. Breggin / Antidepressant-induced harm to self and others
or Teens Taking Antidepressants”, it listed twelve items with bullets. Four are especially relevant to theproduction of violence:
– Feeling very agitated or restless; – New or worse irritability; – Acting aggressive, being angry, or violent; – Acting on dangerous impulses (p. 2). 4.4. Pharmaceutical company responses
As of November 14, 2004 when this author downloaded information from Prozac.com, Zoloft.com
and Paxil.com, none of the information provided by the companies had been updated to meet the newFDA standards. The following information concerning suicide was provided on Prozac: “In addition,patients and their caregivers should be aware of the following information: Depression, as a disease, canbe associated with periods when the symptoms can worsen and thoughts of suicide can emerge. Patientsand their families should watch for these as well as for anxiety, agitation, panic, difficulty sleeping,irritability, hostility, aggressiveness, impulsivity, restlessness, or over excitement and hyperactivity. Callthe doctor if any of these are severe or occur suddenly. Be especially observant at the initiation ofantidepressant drug therapy and when there is a change in dose”.
The above warning material is not contained in a black box and does not make clear that any of these
adverse events are associated with the drug rather than with depression. 5. British regulatory actions
The British began investigating the risks of SSRIs in children before the FDA and helped to spur
the American agency into action. After a series of investigations and reports, on December 10, 2003the Medicines and Healthcare Products Regulatory Agency (MHRA) issued an “Urgent Message” tohealthcare providers that gave a “summary of advice” stating “Paroxetine, venlafaxine, sertraline, citalo-pram and escitalopram are now contraindicated in pediatric MDD in the under 18s” . The MHRAconcluded that the “risk/benefit balance is unfavourable” for children for all of the newer antidepressantsexcept Prozac. (Contrary to the MHRA, the FDA found an increased rate of suicidality for Prozac.) TheMHRA did find an increased rate of mania and hypomania in children compared to adults for Prozac butnot self-harm or suicidal thoughts. For sertraline it found increased rates of agitation, anorexia, insomniaand suicidal thoughts and self-harm. For citalopram, paroxetine and venlafaxine it found increased ratesof self-harm and for escitalopram and fluvoxamine it found no data from clinical trials.
A contraindication for children means that the drug should not be given to them. The FDA has the
power to label the antidepressants contraindicated in children but failed to do so. Furthermore, the Britishdid not add to warnings concerning these drugs for adults.
One year later on December 6, 2004 the MHRA published its conclusions, a Dear Doctor letter, and
new warnings for SSRIs. The MHRA continued to warn about SSRI-induced suicidality in childrenunder eighteen. In its new warnings entitled “Suicidal Thoughts/Behaviour” the agency required the fol-lowing warning  “The use of [any SSRI] has been associated with the development of psychomotorrestlessness, which clinically may be very similar to akathisia, characterized by a subjectively unpleas-ant or distressing restlessness and need to move often unaccompanied by an inability to sit or stand still”(p. 1). P.R. Breggin / Antidepressant-induced harm to self and others
The MHRA also published the “Report of the Focus Group” of the Committee on Safety of Medicines
(CSM) . As a discussion point, the focus group noted in parentheses, “Members of the group com-mented that suicidal ideation and akathisia can happen within a short time of initiating treatment, witha sudden change in dose, or as a consequence of missing a dose or on drug withdrawal”. (This authorhas evaluated cases of akathisia and agitation in association with violence or suicide occurring under allfour of these listed drug conditions: at the start of treatment, at dose changes, after a missed dose, andduring withdrawal.)
Ultimately the British agency concluded that all the SSRIs except Prozac are ineffective in children
and that all (including Prozac) pose some risk of causing suicidality. It banned the use of all SSRIsexcept Prozac in children under age eighteen [31,32]. 6. Canadian regulatory actions
On June 3, 2004, before the FDA issued its formal label changes, Health Canada (the Canadian drug
regulatory agency) issued an Advisory: “Health Canada advises Canadians of stronger warnings forSSRIs and other newer antidepressants”5 .
The advisory made a broader warning than the later U.S. version: “These new warnings indicate that
patients of all ages taking these drugs may experience behavioural and/or emotional changes that mayput them at increased risk of self-harm or harm to others”. Unlike the FDA, Health Canada appliedthe warning to children and adults and warned about both harm to self (suicide) and harm to others(violence).
The advisory described the stimulant syndrome and related it to suicide (harm to self) and violence
(harm to others): “Patients, their families and caregivers should note that a small number of patientstaking drugs of this type may feel worse instead of better, particularly within the first few weeks oftreatment or when doses are adjusted. For example, they may experience unusual feelings of agitation,hostility or anxiety, or have impulsive or disturbing thoughts that could involve self-harm or harm toothers”. (Emphases added.)
The advisory encouraged awareness of the whole range of stimulant-like or activation symptoms for
all age groups: “Doctors are advised to carefully monitor patients of all ages for emotional or behaviouralchanges that may indicate potential for harm, including suicidal thoughts and the onset or worsening ofagitation-type adverse events”.
After consultations with Health Canada, Pfizer upgraded its warnings for Zoloft (sertraline) on May
26, 2004 . In a black boxed warning under the rubric “Adult and Pediatrics: Additional data”, thenew warnings contain some of the basic material in the subsequently published Advisory from HealthCanada, including the risk of both suicide and violence in children and adults: “There are clinical trialand post-marketing reports with SSRIs and other newer antidepressants, in both pediatrics and adults, ofsevere agitation-type adverse events coupled with self-harm or harm to others. The agitation-type eventsinclude: akathisia, agitation, disinhibition, emotional lability, hostility, aggression, depersonalization. Insome cases, the events occurred within several weeks of starting treatment”.
The warning specified, “Rigorous clinical monitoring for suicidal ideation or other indicators of po-
tential for suicidal behavior is advised in patients of all ages. This includes monitoring for agitation-typeemotional and behavioural changes”.
5The drugs addressed by Health Canada were bupropion (Wellbutrin and Zyban), citalopram (Celexa), Fluoxetine (Prozac),
fluvoxamine (Luvox), mirtazapine (Remeron), Paroxetine (Paxil), sertraline (Zoloft) and venlaflaxine (Effexor). P.R. Breggin / Antidepressant-induced harm to self and others
The list of adverse reactions – “akathisia, agitation, disinhibition, emotional lability, hostility, aggres-
sion, depersonalization” – once again underscores the potential risk of violence. The term “disinhibition”does not appear in the FDA lists of adverse effects but is encompassed by several FDA terms such asirritability, agitation, and impulsivity. All of these symptoms are commonly seen in association withviolence. 7. Discussion 7.1. Earlier documentation of the antidepressant-induced stimulant syndrome, violence and suicide
Evidence for the capacity of the newer antidepressants to produce stimulation with violence against
self and others has been accumulating for more than a decade and has been reviewed recently by thisauthor . The evolution of the author’s concept of antidepressant-induced activation or stimulation hasbeen documented since 1992 [2–4,7,9]. Shortly before the FDA hearings, this author summarized :“Mania with psychosis is the extreme end of a stimulant continuum that often begins with lesser degreesof insomnia, nervousness, anxiety, hyperactivity and irritability and then progresses toward more severeagitation, aggression, and varying degrees of mania” (p. 32).
The FDA and Health Canada confirmed my observations when they used almost identical language in
their recent warnings about the risks associated with the newer antidepressants. 7.2. Stimulation as a cause of suicidality and violence
There are at least four stimulant-like syndromes that can lead to violence and suicide :
1. The production of a stimulant continuum that often begins with lesser degrees of insomnia, ner-
vousness, anxiety, hyperactivity and irritability and then progresses toward more severe agitation,aggression, and varying degrees of mania. Mania or manic-like symptoms include disinhibition,grandiosity, sleep disturbances, and out-of-control aggressive behavior, including cycling into de-pression and suicidality.
2. The production of a combined state of stimulation and depression – an agitated depression – with
a high risk of suicide and violence. Often the overall depression is markedly worsened.
3. The production of obsessive preoccupations with aggression against self or others, often accompa-
nied by a worsening of any pre-existing depression.
4. The production of akathisia, an inner agitation or jitteriness that is usually (but not always) ac-
companied by an inability to stop moving. It is sometimes described as psychomotor agitationor restless leg syndrome. The state causes heightened irritability and frustration with aggressionagainst self or others, and often a generally worsening of the mental condition (p. 46). 7.3. Criteria for the diagnosing SSRI-induced violence confirmed by FDA
Based on clinical and forensic experience and research studies, the conditions can be defined under
which SSRI-induced suicide and violence can be diagnosed . Although most cases will not displayall of the criteria, most cases will display one or more of them. As annotated in the following list, therecent FDA and Canadian warnings confirm the essentials of these earlier observations:
1. A relatively sudden onset and rapid escalation of the compulsive aggression against self and/or
P.R. Breggin / Antidepressant-induced harm to self and others– Confirmed in the FDA label’s mention of drug-induced increased depression or suicidality “es-
pecially if these symptoms are severe, abrupt in onset . . .”
2. A recent (typically within two months) initial exposure to the medication, or a recent change in the
dose of the medication, or a recent addition or removal of another psychoactive substance to theregimen. – Confirmed by the FDA label update note that suicidality occurs “especially early during antide-
pressant treatment and when the dose is adjusted up or down”.
3. The presence of other adverse drug reactions, often involving akathisia or stimulation along a
continuum from irritability and agitation to agitated depression and mania. – Confirmed by the FDA’s listing of these events in the label, including akathisia, irritability, agi- – Confirmed by Health Canada linking stimulant effects to the production of harm against self and
4. Resolution of the syndrome after termination of the causative medication, often with a marked
overall improvement in the individual’s mental status. – Not addressed by the FDA.
5. An extremely violent and/or bizarre quality to the thoughts and actions. – Partially confirmed by the FDA’s warning to be alert for antidepressant adverse reactions “espe-
6. An obsessive, compelling, unrelenting quality to the thoughts and actions. – Not addressed by the FDA.
7. An out-of-character quality for the individual as determined by the individual’s history. – Confirmed by the FDA label mention of “unusual changes in behavior” and new symptoms that
“were not part of the patient’s presenting symptoms”.
8. An alien or ego-dystonic quality as determined by the individual’s subjective report. – Not addressed by the FDA. 8. Conclusion
In 2004, drug regulatory agencies in the United States (FDA), Canada (Health Canada) and Great
Britain (MHRA) addressed the issue of antidepressant-induced suicidality in the pediatric population(under age 18). All three agencies confirmed that the new antidepressants cause suicidality in childrenand adolescents, and issued warnings to the public and healthcare professionals. The MHRA banned theuse of the newer antidepressants (except Prozac) in children.
The FDA focused on the SSRIs fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertra-
line (Zoloft), citalopram (Celexa) and escilalopram (Lexapro), as well as venlafaxine (Effexor), mir-tazapine (Remeron), Wellbutrin or Zyban (bupropion) and nefazodone (Serzone). The American agencyrequired a black box warning concerning suicidality in children and additional warnings concerning
P.R. Breggin / Antidepressant-induced harm to self and others
stimulation effects in children and adults, including hostility and aggression. The agency published its“FDA Proposed Medication Guide: About Using Antidepressants in Children and Adults” in which itwarned about patients showing signs of violence on antidepressants, including “new or worse irritabil-ity”, “acting aggressive, being angry, or violent” and “acting on dangerous impulses”.
Health Canada warned that antidepressants cause stimulation or activation in children and adults, in-
cluding a variety of adverse events related to violence, such as agitation, irritability, dyscontrol, hostility,aggression, and mania. Health Canada warned about the risk of harm to self and others in children andadults.
In conclusion, clinicians need to give greater attention to antidepressant-induced activation (stimula-
tion) that can result in both suicidal and violent acts in children and adults. References
 American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-
IV-TR), American Psychiatric Association, Washington, DC, 2000.
 P. Breggin, A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal
syndrome (“crashing”), International Journal of Risk & Safety in Medicine 3 (1992), 325–328.
 P. Breggin, Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Role of the FDA, Springer, New York,
 P. Breggin, Fluvoxamine as a cause of stimulation, mania, and aggression with a critical analysis of the FDA-approved
label, International Journal of Risk and Safety in Medicine 14 (2002), 71–86.
 P. Breggin, Prozac “hazardous” to children, Clinical Psychiatry News 23 (1995), 10.  P. Breggin, Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analy-
sis, International Journal of Risk and Safety in Medicine 16 (2003/2004), 31–49.
 P. Breggin, The Antidepressant Fact Book, Perseus Books, Cambridge, MA, 2001.  P. Breggin (2004, September 13), Presentation at a Public Hearing of the Food and Drug Administration (FDA). Transcript
of Meeting of the Center for Drug Evaluation and Research, pp. 353–354. Joint meeting of the CDER Psychopharmaco-logic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland. www.fda.gov.
 P. Breggin and G. Breggin, Talking Back to Prozac: What Doctors Aren’t Telling You about Today’s Most ControversialDrug, St. Martin’s Press, New York, 1994.
 P. Chesney (2004, September 13), Remarks by P. Joan Chesney, M.D., member of the Pediatric Advisory Committee,
p. 187. Food and Drug Administration. Transcript of Meeting. Center for Drug Evaluation and Research. Joint meetingof the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda,Maryland. www.fda.com.
 G.J. Emslie, Prozac for kids: “Landmark” study affirms drug’s use, Clinical Psychiatry News 23 (1995), 1.  G.J. Emslie, J.H. Heiligenstein, K.D. Wagner, S.L. Hoog, D.E. Ernest, E. Brown, M. Nilsson and J.G. Jacobson, Fluoxetine
for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial, Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002), 1205–1215.
 G.J. Emslie, A.J. Rush, W.A. Weinberg, R.A. Kowatch, C.W. Hughes, T. Carmody and T.J. Rintelmann, A double-blind,
randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression, Archives of General Psy- chiatry 54 (1997), 1031–1037.
 Food and Drug Administration (FDA), FDA issues Public Health Advisory on cautions for use of antidepressants in adults
and children, Rockville, Maryland (2004, March 22). www.fda.gov.
 Food and Drug Administration (FDA), Transcript of Meeting of the Center for Drug Evaluation and Research. Joint
meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland (2004, September 14). www.fda.gov.
 Food and Drug Administration (FDA), Labeling change request letter for antidepressant medication. Rockville, Maryland
 Food and Drug Administration (FDA), FDA proposed medication guide: about using antidepressants in children or
teenagers. Rockville, Maryland (2004, November 3). www.fda.gov.
 T. Hammad, Results of analysis of suicidality in pediatric trials in newer antidepressants. Delivered at the Center for Drug
Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDAPediatric Advisory Committee. Bethesda, Maryland (2004, September 13). P.R. Breggin / Antidepressant-induced harm to self and others
 Health Canada Online, Advisory: Health Canada advises Canadians of stronger warnings for SSRIs and other newer
antidepressants (2004, June 3). www.hc-sc.ca/English/protection/warnings/2004/2004_31.htm.
 D. Healy, Letter from David Healy, M.D. to Peter J. Pitts, Association Commissioner for External Relations, Food and
Drug Administration – Re: Suicidal evidence not addressed by FDA (2004, February 19). www.ahrp.org.
 D. Healy and C. Whitaker, Antidepressants and suicide: Risk-benefit conundrums, Journal of Psychiatry and Neuroscience28 (2003), 331–339.
 http://www.mhra.gov.uk/news/2004/AnnexD.pdf.  J. Jureidini, C. Doecke, P. Mansfield, M. Haby, D. Menkes and A. Tonkin, Efficacy and safety of antidepressants for
children and adolescents, British Medical Journal 328 (2004), 879–883.
 M. Keller, N. Ryan, M. Strober, R. Klein, S. Kutcher, B. Birmaher, G. Emslie, K. Wagner, E.B. Weller, N.C. Winters,
R. Oakes and J.P. McCafferty, Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial, J. Am. Acad. Child. Adolesc. Psychiatry 40 (2001), 762–772.
 A. Khan, S. Kahn, R. Leventhal and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in
antidepressant clinical trials: a replication analysis of the Food and Drug Administration database, International Journal of Neuropsychopharmacology 4 (2001), 113–118.
 A. Khan, H. Warner and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in antidepressant
clinical trials, Archives of General Psychiatry 57 (2000), 311–317.
 I. Kirsch, T. Moore, A. Scoboria and S. Nicholls, The emperor’s new drugs: an analysis of antidepressant medica-
tion data submitted to the US Food and Drug Administration, Prevention and Treatment 5 (2002), Article 23. www. journals.apa.org/prevention/volume5/pre0050023a.html.
 T. Laughren, Regulatory background on antidepressants and suicidality in pediatric patients. Delivered at the Center for
Drug Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and theFDA Pediatric Advisory Committee. Bethesda, Maryland (2004, September 13).
 J. Lenzer, Documents missing from a 10 year old murder case sent to the BMJ, British Medical Journal 329 (2004), 1365.  L. Marangell, S. Yudofsky and J. Silver, Psychopharmacology and electroconvulsive therapy, in: The American Psychiatric Press Textbook of Psychiatry, R. Hales, S. Yudofsky and J. Talbott, eds, 3rd edn, American Psychiatric Press, Washington,DC, 1999, Chapter 27.
 MHRA, [Medicines and Healthcare products Regulatory Agency, Great Britain]. Questions and Answers: Advice on
SSRIs in children from the Committee on Safety of Medicines. Updated February 12, 2004. www.mhra.gov.uk.
 MHRA, [Medicines and Healthcare products Regulatory Agency, Great Britain]. Suicidal thoughts/behavior. December
 T. Moore, Antidepressant drugs and suicidal/aggressive behaviors (2004, January 6). 2021 K Street NW, Suite 800, Wash-
ington, DC 20006. www.DrugSafetyResearch.com.
 A.D. Mosholder, Suicidality in pediatric clinical trials with paroxetine and other antidepressant drugs. Memo from Mosh-
older to Russell Katz, Director, Division of Neuropharmacological Drug Products. Rockville Maryland: Department ofHealth and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2004, February18). www.ahrp.org.
 A.D. Mosholder, Comparison between original ODS and Current DNDP analyses of pediatric suicidality data sets. Deliv-
ered at the Meeting of Psychopharmacological Drugs Advisory Committee and Pediatric Drugs Advisory Committee onSeptember 13, 2004, Bethesda, Maryland.
 Pfizer Canada Inc., Stronger WARNING for SSRIs and other new antidepressants regarding the potential for behavioral
and emotional changes including risk of self harm (2004, May 26). www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/Zoloft.
 C. Whittington, T. Kendall, P. Fonagy, D. Cottrell and E. Boddington, Selective serotonin reuptake inhibitors in childhood
depression: Systematic review of published versus unpublished data, Lancet 363 (2004), 1341–1345.
Everyone needs a home for the holidays . . . Adoption Center Street Address: Hours: Saturdays from Phone: (805)735-6741 Mailing Address: VIVA PO Box 896 Website: http://vivaonline.org Email: [email protected] A NON-PROFIT HUMANE ORGANIZATION DEDICATED TO A BETTER LIFE FOR ALL ANIMALSWhether you send us money or work in the shelter or stay up nightstrappi
Seltene Bluterkrankungen und Meldungen von unerwünschten Arzneimittelwirkungen Zwischenergebnisse der Berliner Fall-Kontroll Surveillance Studie - FAKOS Elisabeth Bronder, Frank Andersohn, Andreas Klimpel, Edeltraut GarbeInstitut für Klinische Pharmakologie, Charité Universitätsmedizin BerlinInstitut für Pharmakoepidemiologie und Technologiebewertung IPTA Berlin10. Jahres